The UT series has been evidenced by in vitro and in vivo experimental data to be more potent than enzalutamide in enzalutamide-resistant castration-resistant prostate cancer cell models and xenografts, especially in ligand binding domain-truncated AR-V7 xenograft [72,73,74,75]. Here, AR is linked to prostate carcinoma.